Missing: Vascular Therapeutics's Product Demo & Case Studies
Promote your product offering to tech buyers.
Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.
Missing: Vascular Therapeutics's Product & Differentiators
Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).
Vascular Therapeutics Frequently Asked Questions (FAQ)
Where is Vascular Therapeutics's headquarters?
Vascular Therapeutics's headquarters is located at 700 East El Camino Real, Mountain View.
What is Vascular Therapeutics's latest funding round?
Vascular Therapeutics's latest funding round is Acquired.
How much did Vascular Therapeutics raise?
Vascular Therapeutics raised a total of $33.85M.
Who are the investors of Vascular Therapeutics?
Investors of Vascular Therapeutics include Glycodesign, AGF Private Equity, GrowthWorks, EGS Healthcare Capital Partners, Vivo Capital and 6 more.
Who are Vascular Therapeutics's competitors?
Competitors of Vascular Therapeutics include Humanetics, Akebia Therapeutics, Altheus Therapeutics, Spiration, Arginetix and 11 more.
Compare Vascular Therapeutics to Competitors
PharmaSurgics develops and commercialises a treatment for the prevention of harmful scarring (adhesions)
Photopharmica, developing light sensitive drugs for the prevention and treatment of diseases in the anti-infective and oncology markets photosensitisers, for industrial applications
Ash Access Technology is developing and commercializing products that address high unmet need in the area of vascular access-related complications with a focus on infectious disease therapies and device performance.
We are a biopharmaceutical company developing and commercializing therapies for vascular disorders. Our research and development efforts are focused on therapies for stroke and other vascular disorders, using our proprietary microbubble technology to treat vascular occlusions, or blood vessel blockages, as well as the resulting ischemia, which is tissue damage caused by a reduced supply of oxygen. In addition to the brain and the lungs, blood clots can block blood flow and cause damage to other tissues in the body such as the heart, in case of coronary arterial disease, and the legs and other extremities, in case of peripheral vascular disease. We believe our development and research stage products may address significant unmet medical needs not only for stroke but also for clot-induced damage in tissues other than the brain.
Cryptopharma is a Company focused on the discovery and development of anti-inflammatory therapeutic agents for treatment of pulmonary diseases. The company's initial focus is on the development of CP92, a treatment of Cystic Fibrosis. Second generation compounds are in development with the potential to treat other inflammatory conditions including asthma and chronic obstructive pulmonary disease (COPD). See www.cryptopharma.com
SYNAPSIN is developing therapeutic strategies for the treatmentand prevention ofneurodegenerative disorders such as Alzheimer's disease (AD),Parkinson's disease, Amyotrophic Lateral Sclerosis (ALS), and spinal cord injury.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.